A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0

PLoS One. 2018 Apr 12;13(4):e0195690. doi: 10.1371/journal.pone.0195690. eCollection 2018.

Abstract

Objectives: To investigate the association between lower urinary-tract infections, their associated antibiotics and the subsequent risk of developing PCa.

Subjects/patients (or materials) and methods: Using data from the Swedish PCBaSe 3.0, we performed a matched case-control study (8762 cases and 43806 controls). Conditional logistic regression analysis was used to assess the association between lower urinary-tract infections, related antibiotics and PCa, whilst adjusting for civil status, education, Charlson Comorbidity Index and time between lower urinary-tract infection and PCa diagnosis.

Results: It was found that lower urinary-tract infections did not affect PCa risk, however, having a lower urinary-tract infection or a first antibiotic prescription 6-12 months before PCa were both associated with an increased risk of PCa (OR: 1.50, 95% CI: 1.23-1.82 and 1.96, 1.71-2.25, respectively), as compared to men without lower urinary-tract infections. Compared to men with no prescriptions for antibiotics, men who were prescribed ≥10 antibiotics, were 15% less likely to develop PCa (OR: 0.85, 95% CI: 0.78-0.91).

Conclusion: PCa was not found to be associated with diagnosis of a urinary-tract infection or frequency, but was positively associated with short time since diagnoses of lower urinary-tract infection or receiving prescriptions for antibiotics. These observations can likely be explained by detection bias, which highlights the importance of data on the diagnostic work-up when studying potential risk factors for PCa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Case-Control Studies
  • Databases, Factual*
  • Humans
  • Male
  • Middle Aged
  • Prostatic Neoplasms / complications*
  • Prostatic Neoplasms / epidemiology*
  • Risk Assessment
  • Urinary Tract Infections / complications*
  • Urinary Tract Infections / drug therapy*

Substances

  • Anti-Bacterial Agents

Grants and funding

This work was supported by the Swedish Research Council for Working Life, Health, and Welfare (825-2012-5047), the Swedish Cancer Society (14- 0570), the Cancer Society in Stockholm, and Uppsala County council. The research was also supported by the National Institute for Health Research (NIHR) BRC based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.